Background: Systemic sclerosis (SSc) is an autoimmune disease characterized by dysregulation of the immune system, vasculopathy and fibrosis of the skin and internal organs. Natural Killer (CD56 + CD3 -, NK) and NKT-like (CD56 + CD3 + ) cells display receptors (NKR) whose expression pattern determines their cytotoxic and immune-regulatory activity. The role of NK and NKT-like cells in the dysregulation of the immune system in SSc has not been fully elucidated yet. Objectives: To improve our knowledge on the contribution of NK, NKT-like and a subset of NKT cells expressing invariant TCR (iNKT) in SSc development, we performed a broad phenotyping of NKR in the circulation of SSc patients, including subjects with pre-clinical SSc. Methods: NKR were assessed by flow cytometry using two 13-color panels on whole blood of 84 SSc patients and 20 healthy controls (HC Background: Type VII collagen (col7) is the main component of the anchoring fibrils that connects the basement membrane to the underlying interstitial matrix and has mainly been investigated for its role in blistering skin diseases. It has been investigated for its role in dystrophic epidermolysis bullosa, a severe skin disease. Furthermore, increased levels of type VII collagen in skin has been reported for patients with systemic sclerosis (SSc). Objectives: The objective was to develop and characterize a blood-based marker assessing col7 degradation in patients with SSc. Methods: We identified a specific fragment of col7 in serum from COPD patients, which was not found in controls, using mass spectrometry. A monoclonal antibody was raised against the first ten amino acids of the neo-epitope (KLH-CGG-GPPGPPGRLV) and employed in a competitive ELISA (C7M). The C7M assay was validated technically and was subsequently evaluated in 2 cohorts including SSc patients. The first cohort (SSc#1; n=35) consisted of early (<2 years of SSc symptoms; n=16) and late (>10 years of disease with stable skin for at least 6 months, n=19) diffuse SSc patients, while the second cohort (SSc#2; n=119) consisted of limited (n=78) and diffuse (n=41) SSc patients. Serum C7M levels were likewise measured in healthy subjects and compared to the levels of SSc patients using the Kruskal-Wallis test with Dunn's multiple comparisons test comparing healthy individuals with the two SSc cohorts. Results: A technically robust competitive ELISA (C7M), which was highly specific for a col7 fragment was developed. The assay showed acceptable inter-(13%) and intra-assay (9%) variation, linearity (102% dilution recovery), analyte stability (102% recovery after 4 freeze/thaw cycles), and interference. The C7M marker was evaluated by comparing serum levels in healthy donors with patients with SSc ( Figure) . Serum C7M levels were not associated with age, gender, BMI, or disease duration. The geometric mean serum C7M level in healthy donors was 4.6 ng/mL (95% CI 3.7-5.6 ng/mL). The geometric mean serum C7M levels were significantly elevated in both cohorts of patients with SSc (SSc#1, 13.6 ng/mL [95% CI 11.1-16.5], p<0.0001; SSc#2, 9.2 ng/mL [95% CI 8.3-10.2], p<0.0001). Furthermore, a significant difference were observed between the two cohorts (P=0.05).
Conclusions:
The C7M ELISA enabled quantification of type VII collagen degradation in serum. Elevated serum C7M levels indicated that the remodeling of type VII collagen was significantly increased in patients with SSc, suggesting a pathological role.
